Top 5 Stocks to Buy Now
→ Stranded On The Flood Plains of History (From Porter & Company) (Ad)tc pixel Free APT Stock Alerts

Alpha Pro Tech (APT) Competitors

Alpha Pro Tech logo
$5.17 -0.14 (-2.64%)
As of 04:00 PM Eastern
Compare

APT vs. LUCD, PDEX, SMTI, RXST, and INFU

Should you buy Alpha Pro Tech stock or one of its competitors? MarketBeat compares Alpha Pro Tech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Pro Tech include Lucid Diagnostics (LUCD), Pro-Dex (PDEX), Sanara MedTech (SMTI), RxSight (RXST), and InfuSystem (INFU). These companies are all part of the "medical equipment" industry.

How does Alpha Pro Tech compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Alpha Pro Tech has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucid Diagnostics$4.71M44.41-$58.01M-$0.47N/A
Alpha Pro Tech$59.91M0.88$4.19M$0.3514.77

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 16.2% of Alpha Pro Tech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alpha Pro Tech has a net margin of 6.99% compared to Lucid Diagnostics' net margin of -876.72%. Alpha Pro Tech's return on equity of 6.70% beat Lucid Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics-876.72% N/A -116.26%
Alpha Pro Tech 6.99%6.70%5.76%

Lucid Diagnostics presently has a consensus price target of $4.19, suggesting a potential upside of 306.55%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Alpha Pro Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Alpha Pro Tech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Lucid Diagnostics' average media sentiment score of 0.00 equaled Alpha Pro Tech'saverage media sentiment score.

Company Overall Sentiment
Lucid Diagnostics Neutral
Alpha Pro Tech Neutral

Summary

Alpha Pro Tech beats Lucid Diagnostics on 8 of the 14 factors compared between the two stocks.

How does Alpha Pro Tech compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Pro-Dex had 2 more articles in the media than Alpha Pro Tech. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Alpha Pro Tech. Pro-Dex's average media sentiment score of 0.00 equaled Alpha Pro Tech'saverage media sentiment score.

Company Overall Sentiment
Pro-Dex Neutral
Alpha Pro Tech Neutral

Pro-Dex has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Pro-Dex has a net margin of 16.08% compared to Alpha Pro Tech's net margin of 6.99%. Pro-Dex's return on equity of 22.78% beat Alpha Pro Tech's return on equity.

Company Net Margins Return on Equity Return on Assets
Pro-Dex16.08% 22.78% 14.30%
Alpha Pro Tech 6.99%6.70%5.76%

Pro-Dex currently has a consensus target price of $70.00, indicating a potential upside of 10.43%. Given Pro-Dex's stronger consensus rating and higher probable upside, equities research analysts clearly believe Pro-Dex is more favorable than Alpha Pro Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pro-Dex
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Alpha Pro Tech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by insiders. Comparatively, 16.2% of Alpha Pro Tech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pro-Dex has higher revenue and earnings than Alpha Pro Tech. Alpha Pro Tech is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pro-Dex$66.59M3.04$8.98M$3.6217.51
Alpha Pro Tech$59.91M0.88$4.19M$0.3514.77

Summary

Pro-Dex beats Alpha Pro Tech on 13 of the 15 factors compared between the two stocks.

How does Alpha Pro Tech compare to Sanara MedTech?

Alpha Pro Tech (NYSE:APT) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

22.7% of Alpha Pro Tech shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 16.2% of Alpha Pro Tech shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alpha Pro Tech has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Alpha Pro Tech has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Pro Tech$59.91M0.88$4.19M$0.3514.77
Sanara MedTech$103.12M1.93-$37.56M-$3.77N/A

In the previous week, Sanara MedTech had 2 more articles in the media than Alpha Pro Tech. MarketBeat recorded 2 mentions for Sanara MedTech and 0 mentions for Alpha Pro Tech. Sanara MedTech's average media sentiment score of 2.00 beat Alpha Pro Tech's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company Overall Sentiment
Alpha Pro Tech Neutral
Sanara MedTech Very Positive

Alpha Pro Tech has a net margin of 6.99% compared to Sanara MedTech's net margin of -31.23%. Alpha Pro Tech's return on equity of 6.70% beat Sanara MedTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Pro Tech6.99% 6.70% 5.76%
Sanara MedTech -31.23%-3.19%-0.56%

Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 56.32%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech is more favorable than Alpha Pro Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Pro Tech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Sanara MedTech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Summary

Sanara MedTech beats Alpha Pro Tech on 10 of the 17 factors compared between the two stocks.

How does Alpha Pro Tech compare to RxSight?

RxSight (NASDAQ:RXST) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

RxSight currently has a consensus price target of $9.44, suggesting a potential upside of 80.93%. Given RxSight's stronger consensus rating and higher probable upside, research analysts plainly believe RxSight is more favorable than Alpha Pro Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.93
Alpha Pro Tech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Alpha Pro Tech has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RxSight$134.48M1.61-$38.94M-$1.13N/A
Alpha Pro Tech$59.91M0.88$4.19M$0.3514.77

Alpha Pro Tech has a net margin of 6.99% compared to RxSight's net margin of -36.58%. Alpha Pro Tech's return on equity of 6.70% beat RxSight's return on equity.

Company Net Margins Return on Equity Return on Assets
RxSight-36.58% -17.01% -15.12%
Alpha Pro Tech 6.99%6.70%5.76%

78.8% of RxSight shares are held by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 16.2% of Alpha Pro Tech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, RxSight had 1 more articles in the media than Alpha Pro Tech. MarketBeat recorded 1 mentions for RxSight and 0 mentions for Alpha Pro Tech. RxSight's average media sentiment score of 0.00 equaled Alpha Pro Tech'saverage media sentiment score.

Company Overall Sentiment
RxSight Neutral
Alpha Pro Tech Neutral

RxSight has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Summary

RxSight beats Alpha Pro Tech on 8 of the 15 factors compared between the two stocks.

How does Alpha Pro Tech compare to InfuSystem?

Alpha Pro Tech (NYSE:APT) and InfuSystem (NYSE:INFU) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Alpha Pro Tech has a net margin of 6.99% compared to InfuSystem's net margin of 1.12%. Alpha Pro Tech's return on equity of 6.70% beat InfuSystem's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Pro Tech6.99% 6.70% 5.76%
InfuSystem 1.12%2.78%1.41%

Alpha Pro Tech has higher earnings, but lower revenue than InfuSystem. Alpha Pro Tech is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Pro Tech$59.91M0.88$4.19M$0.3514.77
InfuSystem$142.40M1.29$870K$0.3823.89

Alpha Pro Tech has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

In the previous week, InfuSystem had 1 more articles in the media than Alpha Pro Tech. MarketBeat recorded 1 mentions for InfuSystem and 0 mentions for Alpha Pro Tech. InfuSystem's average media sentiment score of 1.95 beat Alpha Pro Tech's score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company Overall Sentiment
Alpha Pro Tech Neutral
InfuSystem Very Positive

InfuSystem has a consensus target price of $15.00, indicating a potential upside of 65.20%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Alpha Pro Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Pro Tech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
InfuSystem
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

22.7% of Alpha Pro Tech shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 16.2% of Alpha Pro Tech shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

InfuSystem beats Alpha Pro Tech on 11 of the 16 factors compared between the two stocks.

Get Alpha Pro Tech News Delivered to You Automatically

Sign up to receive the latest news and ratings for APT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APT vs. The Competition

Export
MetricAlpha Pro TechSurgical appliances & supplies IndustryIndustrials SectorNYSE Exchange
Market Cap$54.25M$21.70M$9.73B$23.27B
Dividend YieldN/AN/A3.55%4.07%
P/E Ratio13.9713.9725.7331.08
Price / Sales0.881.314,867.9721.85
Price / Cash12.8012.8027.9324.45
Price / Book0.981.244.614.64
Net Income$4.19M-$3.92M$793.53M$1.07B
7 Day Performance-1.71%-7.36%-0.07%-1.04%
1 Month Performance-17.54%2.98%0.18%0.18%
1 Year Performance8.61%-31.65%25.08%24.25%

Alpha Pro Tech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APT
Alpha Pro Tech
N/A$5.17
-2.6%		N/A+11.8%$54.25M$59.91M13.97120
LUCD
Lucid Diagnostics
4.0461 of 5 stars		$1.07
-1.4%		$4.19
+293.2%		-18.3%$216.27M$4.71MN/A70
PDEX
Pro-Dex
2.1206 of 5 stars		$64.37
flat		$70.00
+8.7%		+58.9%$205.34M$66.59M17.78140
SMTI
Sanara MedTech
2.7004 of 5 stars		$22.02
flat		$34.00
+54.4%		-20.3%$201.70M$103.12MN/A60
RXST
RxSight
2.5244 of 5 stars		$4.73
flat		$9.44
+99.7%		-63.6%$195.82M$134.48MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:APT) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel